FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W36679969> ?p ?o ?g. }

• W36679969 endingPage "807" @default.
• W36679969 startingPage "803" @default.
• W36679969 abstract "Abstract NAD(P)H:quinone oxidoreductase (NQO1) converts benzene-derived quinones to less toxic hydroquinones and has been implicated in benzene-associated hematotoxicity. A point mutation in codon 187 (Pro to Ser) results in complete loss of enzyme activity in homozygous subjects, whereas those with 2 wild-type alleles have normal activity. The frequency of homozygosity for the mutant allele among Caucasians and African Americans is 4% to 5% but is higher in Hispanics and Asians. Using an unambiguous polymerase chain reaction (PCR) method, we assayed nonmalignant lymphoblastoid cell lines derived from 104 patients with myeloid leukemias; 56 had therapy-related acute myeloid leukemia (t-AML), 30 had a primary myelodysplastic syndrome (MDS), 9 had AML de novo, and 9 had chronic myelogenous leukemia (CML). All patients had their leukemia cells karyotyped. Eleven percent of the t-AML patients were homozygous and 41% were heterozygous for the NQO1 polymorphism; these proportions were significantly higher than those expected in a population of the same ethnic mix (P = .036). Of the 45 leukemia patients who had clonal abnormalities of chromosomes 5 and/or 7, 7 (16%) were homozygous for the inactivating polymorphism, 17 (38%) were heterozygous, and 21 (47%) had 2 wild-type alleles for NQO1. Thus, NQO1 mutations were significantly increased compared with the expected proportions: 5%, 34%, and 61%, respectively (P= .002). An abnormal chromosome no. 5 or 7 was observed in 7 of 8 (88%) homozygotes, 17 of 45 (38%) heterozygotes, and 21 of 51 (41%) patients with 2 wild-type alleles. Among 33 patients with balanced translocations [14 involving bands 11q23 or 21q22, 10 with inv(16) or t(15;17), and 9 with t(9;22)], there were no homozygotes, 15 (45%) heterozygotes, and 18 (55%) with 2 wild-type alleles. Whereas fewer than 3 homozygotes were expected among the 56 t-AML patients, 6 were observed; 19 heterozygotes were expected, but 23 were observed. The gene frequency for the inactivating polymorphism (0.31) was increased approximately 1.4-fold among the 56 t-AML patients. This increase was observed within each of the following overlapping cohorts of t-AML patients: the 43 who had received an alkylating agent, the 27 who had received a topoisomerase II inhibitor, and the 37 who had received any radiotherapy. Thus, the frequency of an inactivating polymorphism in NQO1 appears to be increased in this cohort of myeloid leukemias, especially among those with t-AML or an abnormality of chromosomes 5 and/or 7. Homozygotes and heterozygotes (who are at risk for treatment-induced mutation or loss of the remaining wild-type allele in their hematopoietic stem cells) may be particularly vulnerable to leukemogenic changes induced by carcinogens." @default.
• W36679969 created "2016-06-24" @default.
• W36679969 creator A5029088944 @default.
• W36679969 creator A5035759211 @default.
• W36679969 creator A5043076766 @default.
• W36679969 creator A5050811525 @default.
• W36679969 creator A5068037678 @default.
• W36679969 creator A5072355780 @default.
• W36679969 creator A5072420982 @default.
• W36679969 date "1999-07-15" @default.
• W36679969 modified "2023-10-05" @default.
• W36679969 title "Prevalence of the Inactivating 609C→T Polymorphism in the NAD(P)H:Quinone Oxidoreductase (NQO1) Gene in Patients With Primary and Therapy-Related Myeloid Leukemia" @default.
• W36679969 cites W1796305773 @default.
• W36679969 cites W1808908305 @default.
• W36679969 cites W1974176317 @default.
• W36679969 cites W1980787460 @default.
• W36679969 cites W1990780198 @default.
• W36679969 cites W2004799276 @default.
• W36679969 cites W2024238421 @default.
• W36679969 cites W2058536932 @default.
• W36679969 cites W2083912192 @default.
• W36679969 cites W2084444653 @default.
• W36679969 cites W2111863880 @default.
• W36679969 cites W2287952 @default.
• W36679969 cites W2288473528 @default.
• W36679969 cites W2321127718 @default.
• W36679969 cites W2321161015 @default.
• W36679969 cites W2412698214 @default.
• W36679969 doi "https://doi.org/10.1182/blood.v94.2.803" @default.
• W36679969 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10397748" @default.
• W36679969 hasPublicationYear "1999" @default.
• W36679969 type Work @default.
• W36679969 sameAs 36679969 @default.
• W36679969 citedByCount "274" @default.
• W36679969 countsByYear W366799692012 @default.
• W36679969 countsByYear W366799692013 @default.
• W36679969 countsByYear W366799692014 @default.
• W36679969 countsByYear W366799692015 @default.
• W36679969 countsByYear W366799692016 @default.
• W36679969 countsByYear W366799692017 @default.
• W36679969 countsByYear W366799692018 @default.
• W36679969 countsByYear W366799692019 @default.
• W36679969 countsByYear W366799692020 @default.
• W36679969 countsByYear W366799692021 @default.
• W36679969 countsByYear W366799692022 @default.
• W36679969 countsByYear W366799692023 @default.
• W36679969 crossrefType "journal-article" @default.
• W36679969 hasAuthorship W36679969A5029088944 @default.
• W36679969 hasAuthorship W36679969A5035759211 @default.
• W36679969 hasAuthorship W36679969A5043076766 @default.
• W36679969 hasAuthorship W36679969A5050811525 @default.
• W36679969 hasAuthorship W36679969A5068037678 @default.
• W36679969 hasAuthorship W36679969A5072355780 @default.
• W36679969 hasAuthorship W36679969A5072420982 @default.
• W36679969 hasConcept C104317684 @default.
• W36679969 hasConcept C126322002 @default.
• W36679969 hasConcept C143589142 @default.
• W36679969 hasConcept C153911025 @default.
• W36679969 hasConcept C180754005 @default.
• W36679969 hasConcept C203014093 @default.
• W36679969 hasConcept C2778461978 @default.
• W36679969 hasConcept C2778729363 @default.
• W36679969 hasConcept C2779282312 @default.
• W36679969 hasConcept C502942594 @default.
• W36679969 hasConcept C54355233 @default.
• W36679969 hasConcept C71924100 @default.
• W36679969 hasConcept C86803240 @default.
• W36679969 hasConceptScore W36679969C104317684 @default.
• W36679969 hasConceptScore W36679969C126322002 @default.
• W36679969 hasConceptScore W36679969C143589142 @default.
• W36679969 hasConceptScore W36679969C153911025 @default.
• W36679969 hasConceptScore W36679969C180754005 @default.
• W36679969 hasConceptScore W36679969C203014093 @default.
• W36679969 hasConceptScore W36679969C2778461978 @default.
• W36679969 hasConceptScore W36679969C2778729363 @default.
• W36679969 hasConceptScore W36679969C2779282312 @default.
• W36679969 hasConceptScore W36679969C502942594 @default.
• W36679969 hasConceptScore W36679969C54355233 @default.
• W36679969 hasConceptScore W36679969C71924100 @default.
• W36679969 hasConceptScore W36679969C86803240 @default.
• W36679969 hasIssue "2" @default.
• W36679969 hasLocation W366799691 @default.
• W36679969 hasOpenAccess W36679969 @default.
• W36679969 hasPrimaryLocation W366799691 @default.
• W36679969 hasRelatedWork W1481453705 @default.
• W36679969 hasRelatedWork W1624270399 @default.
• W36679969 hasRelatedWork W1961168765 @default.
• W36679969 hasRelatedWork W2054298289 @default.
• W36679969 hasRelatedWork W2057739827 @default.
• W36679969 hasRelatedWork W2099143831 @default.
• W36679969 hasRelatedWork W2170293083 @default.
• W36679969 hasRelatedWork W2388787066 @default.
• W36679969 hasRelatedWork W4231766842 @default.
• W36679969 hasRelatedWork W4238882508 @default.
• W36679969 hasVolume "94" @default.
• W36679969 isParatext "false" @default.
• W36679969 isRetracted "false" @default.
• W36679969 magId "36679969" @default.

• next